Reviva Pharmaceuticals Holdings, Inc.: current accounts payable
Current accounts payable for Reviva Pharmaceuticals Holdings, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Reviva Pharmaceuticals Holdings, Inc. financial histories
What this measure means
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
Exact concept: us-gaap:AccountsPayableCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-02-28 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 3,009,074 | USD | 2026-03-30 | 10-K · 0001437749-26-010126 |
| At date | 2024-12-31 | 6,283,430 | USD | 2026-03-30 | 10-K · 0001437749-26-010126 |
| At date | 2023-12-31 | 3,849,108 | USD | 2025-04-03 | 10-K · 0001437749-25-010791 |
| At date | 2022-12-31 | 3,520,271 | USD | 2024-04-15 | 10-K · 0001437749-24-011955 |
| At date | 2021-12-31 | 509,583 | USD | 2023-03-30 | 10-K · 0001437749-23-008502 |
| At date | 2020-12-31 | 1,008,046 | USD | 2022-03-15 | 10-K · 0001437749-22-006332 |
| At date | 2020-02-29 | 299,653 | USD | 2020-05-04 | 10-K · 0001104659-20-055760 |
| At date | 2019-12-31 | 224,543 | USD | 2021-05-07 | 10-K/A · 0001437749-21-011375 |
| At date | 2019-02-28 | 23,050 | USD | 2020-05-04 | 10-K · 0001104659-20-055760 |
Related financial histories
- Reviva Pharmaceuticals Holdings, Inc.: total assets
- Reviva Pharmaceuticals Holdings, Inc.: total liabilities
- Reviva Pharmaceuticals Holdings, Inc.: stockholders equity
- Reviva Pharmaceuticals Holdings, Inc.: cash and cash equivalents
- Reviva Pharmaceuticals Holdings, Inc.: net income or loss
- Reviva Pharmaceuticals Holdings, Inc.: operating cash flow
- Reviva Pharmaceuticals Holdings, Inc.: financing cash flow
- Reviva Pharmaceuticals Holdings, Inc.: retained earnings or deficit
- Reviva Pharmaceuticals Holdings, Inc.: basic weighted-average shares
- Reviva Pharmaceuticals Holdings, Inc.: basic earnings per share
- Reviva Pharmaceuticals Holdings, Inc.: income tax expense or benefit
- Reviva Pharmaceuticals Holdings, Inc.: net property, plant and equipment
- Reviva Pharmaceuticals Holdings, Inc.: share-based compensation expense
- Reviva Pharmaceuticals Holdings, Inc.: operating income or loss
- Reviva Pharmaceuticals Holdings, Inc.: current assets
- Reviva Pharmaceuticals Holdings, Inc.: interest expense
- Reviva Pharmaceuticals Holdings, Inc.: current liabilities
- Reviva Pharmaceuticals Holdings, Inc.: operating expenses
- Reviva Pharmaceuticals Holdings, Inc.: research and development expense
Inspect the source
- Entity
- Reviva Pharmaceuticals Holdings, Inc. / CIK 0001742927
- Captured
- 2026-09-19T11:20:56.685Z
- SEC response SHA-256
26f740ff1a169faebcba46f28197dc15a1be7bab2feb9b4952e7b7f15df066e6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001742927.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))